Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
- PMID: 9084785
- DOI: 10.1097/00002030-199704000-00001
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
Abstract
Objective: The most important hepatic enzyme involved in the metabolism of protease inhibitors is cytochrome P450 3A4 (CYP3A4). Ritonavir (RIT) is a potent inhibitor of CYP3A4 and inhibits saquinavir (SQV) metabolism in healthy volunteers. In this study we investigated the kinetics of SQV when administered alone and in combination with RIT in HIV-infected patients.
Design: SQV pharmacokinetics were determined in seven patients who had advanced HIV disease. Steady-state SQV profiles were obtained on two occasions following treatment with SQV 600 mg three times daily alone and when administered with RIT 300 mg twice daily.
Methods: Blood samples were obtained at times 0, 1, 2, 4, 6 and 8 h post-dosing. Following centrifugation, separated plasma was heated at 58 degrees C for at least 30 min to inactivate HIV and stored at -80 degrees C until analysis using high performance liquid chromatography.
Results: For patients treated with SQV alone there was a 12-fold variability in the area under the SQV concentration-time curve (AUC0-8h) ranging from 293 to 3446 ng.h/ml. When combined with RIT there was a marked increase in the maximum plasma concentration of SQV [median (range), 146 (57-702) versus 4795 (1420-15810) ng/ml; approximately 95% confidence interval (CI), 2988-6819; P = 0.0006, Mann-Whitney U test]. The AUC0-8h for SQV was also significantly increased in the presence of RIT [median (range), 470 (29-3446) versus 27,458 (7357-108,001) ng.h/ml; approximately 95% CI, 16,628-35,111; P = 0.0006].
Conclusions: For some patients, administration of SQV 600 mg three times daily results in very low SQV plasma levels and possibly little antiviral effect. Combination of SQV with RIT results in a significant drug interaction mediated by enzyme inhibition which exposes patients to very high SQV concentrations and potential toxicity. If combination therapy with SQV plus RIT is considered then the dose of SQV should be greatly reduced.
Similar articles
-
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):344-9. doi: 10.1097/00126334-200108010-00004. J Acquir Immune Defic Syndr. 2001. PMID: 11468422 Clinical Trial.
-
Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients.AIDS. 1997 Dec;11(15):F117-20. doi: 10.1097/00002030-199715000-00001. AIDS. 1997. PMID: 9412695
-
Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.Eur J Med Res. 1999 Mar 26;4(3):101-4. Eur J Med Res. 1999. PMID: 10085276 Clinical Trial.
-
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.Antivir Ther. 2001 Dec;6(4):201-29. Antivir Ther. 2001. PMID: 11878403 Review.
-
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.Clin Pharmacokinet. 2000 Jan;38(1):41-57. doi: 10.2165/00003088-200038010-00003. Clin Pharmacokinet. 2000. PMID: 10668858 Review.
Cited by
-
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.Clin Pharmacokinet. 1998 Oct;35(4):275-91. doi: 10.2165/00003088-199835040-00002. Clin Pharmacokinet. 1998. PMID: 9812178 Review.
-
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.Br J Clin Pharmacol. 1998 Apr;45(4):355-9. doi: 10.1046/j.1365-2125.1998.t01-1-00687.x. Br J Clin Pharmacol. 1998. PMID: 9578182 Free PMC article. Clinical Trial.
-
Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.Clin Pharmacokinet. 2016 Feb;55(2):237-47. doi: 10.1007/s40262-015-0312-0. Clin Pharmacokinet. 2016. PMID: 26341813 Clinical Trial.
-
Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.Antimicrob Agents Chemother. 2000 Sep;44(9):2575-7. doi: 10.1128/AAC.44.9.2575-2577.2000. Antimicrob Agents Chemother. 2000. PMID: 10952623 Free PMC article.
-
Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.Br J Clin Pharmacol. 2001 Sep;52(3):255-64. doi: 10.1046/j.0306-5251.2001.01452.x. Br J Clin Pharmacol. 2001. PMID: 11560557 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical